natgillin/translations-raw huggingface dataset:
The metering pump is comprised of an outer bottle with a pouch liner, a metering pump and a cap.
Odmerna črpalka je sestavljena iz zunanje steklenice s prevleko, odmerne črpalke in zaporke.
The metering pump is comprised of an outer polypropylene bottle with a Low Density Polyethylene (LDPE) pouch liner, a polypropylene metering pump, with ethylene propylene diene monomer (EPDM) gaskets, and a polypropylene cap.
Odmerna črpalka je sestavljena iz zunanje polipropilenske steklenice s prevleko za vrečko iz polietilena majhne gostote (LDPE), polipropilenske odmerne črpalke, s tesnili iz monomera etilenpropilendiena (EPDM) in polipropilenske zaporke.
The methadone dose was increased by a mean of 22% to alleviate withdrawal symptoms.
odmerek metadona, kolikor je to
The methadone dose was increased by a mean of 22% to alleviate withdrawal symptoms.
Za ublažitev odtegnitvenih simptomov so povečali odmerek metadona v povprečju za 22 %.
The method of administration and timing of medicine intake
z načinom dajanja in časovnim razporedom jemanja zdravila;
The method of administration is by coarse spray by using a suitable device (volume delivered: 28 ml/100 chicks, droplet size: 200–250 µm and working pressure: 2 to 3 bars).
Način uporabe zdravila je pršenje z večjimi kapljicami z uporabo primernega pripomočka (količina dovajanja: 28 ml/100 piščancev, velikost kapljic: 200–250 µm in delovni tlak: 2 do 3 bare).
The method of preparation of NexoBrid and of its application to wound area
Način priprave zdravila NexoBrid in aplikacije na predel rane
The method used to estimate renal function (CrCL in mL/min) during the clinical development of Lixiana was the Cockcroft-Gault method.
Metoda, uporabljena za oceno delovanja ledvic (CrCL v ml/min) med kliničnim razvojem zdravila Lixiana, je bila Cockcroft-Gaultova metoda.
The method used to estimate renal function (CrCL in mL/min) during the clinical development of Pradaxa was the Cockcroft-Gault method (see section 4.2 Pradaxa 75 mg).
Med kliničnim razvojem zdravila Pradaxa so ledvično delovanje (CrCl v ml/min) ocenjevali po Cockcroft-Gaultovi metodi (glejte poglavje 4.2 pri Pradaxa 75 mg).
The method used to estimate renal function (CrCL in mL/min) during the clinical development of Pradaxa was the Cockcroft-Gault method.
Med kliničnim razvojem zdravila Pradaxa so ledvično delovanje (CrCl v ml/min) ocenjevali po Cockcroft-Gaultovi metodi.
The method used to estimate renal function (CrCL in mL/min) during the clinical development of Pradaxa was the Cockcroft-Gault method. (see section 4.2 Pradaxa 75 mg)
Med kliničnim razvojem zdravila Pradaxa so ledvično delovanje (CrCl v ml/min) ocenjevali po Cockcroft-Gaultovi metodi (glejte poglavje 4.2 pri Pradaxa 75 mg).
The method validated in the application is as follows:
Metoda validirana za opisano rabo je naslednja:
The MIC and MBC data are reported from a representative sample of isolates from field materials within different EU geographic areas.
MIK in MBK podatki so pridobljeni iz reprezentativnih vzorcev izolatov s terena iz različnih geografskih področij EU.
The microbiological data suggest that posaconazole is active against Rhizomucor, Mucor, and Rhizopus, however the clinical data are currently too limited to assess the efficacy of posaconazole against these causative agents.
Mikrobiološki podatki kažejo, da je posakonazol učinkovit proti vrstam Rhizomucor, Mucor in Rhizopus, vendar je kliničnih podatkov trenutno premalo, da bi lahko ocenili učinkovitost posakonazola proti tem povzročiteljem okužb.
The microbubble dispersion is prepared before use by injecting through the septum 5 ml of sodium chloride 9 mg/ml (0.9%) solution for injection to the contents of the vial.
Disperzijo mikromehurčkov pripravimo neposredno pred uporabo z vbrizganjem 5 ml 9 mg/ml (0,9%) raztopine natrijevega klorida za injiciranje skozi zamašek k vsebini v viali.
The midazolam half- life was increased about 2.5-fold.
Razpolovni čas midazolama se je podaljšal za približno 2,5-krat.
The minimal data elements to be transmitted in individual case safety reports in order to facilitate the evaluation and the identification of the vaccine administered to each subject, including the invented name, the vaccine manufacturer and the batch number.
Minimalne podatkovne elemente, ki jih je treba sporočiti v vsakem poročilu, da se olajša vrednotenje in identifikacija uporabljenega cepiva pri posamezni osebi, vključno z imenom cepiva, izdelovalcem in številko serije.
The minimal data elements to be transmitted in individual case safety reports in order to facilitate the evaluation and the identification of the vaccine administered to each subject, including the invented name, the vaccine manufacturer and the batch number.
Minimalne podatkovne elemente, ki jih je treba sporočiti v vsakem poročilu, da se olajša vrednotenje in identifikacija uporabljenega cepiva pri posamezni osebi, vključno z imenom cepiva, izdelovalcem ter številko serije.
The minimal specific activity is 3,700 MBq Copper-64/micrograms of Copper at the expiry date and time.
Minimalna specifična aktivnost je 3 700 MBq bakra (64Cu)/mikrogram bakra na datum in čas izteka roka uporabnosti.
The minimal specific activity is 3,700 MBq Copper-64/micrograms of Copper at the expiry date and time.
Minimalna specifična aktivnost je 3 700 MBq bakra-64/mikrogram bakra na datum in čas izteka roka uporabnosti.
The Minimum Alveolar Concentration (MAC) of sevoflurane in dogs is 2.36%.
Minimalna alveolarna koncentracija (MAC) sevoflurana pri psih je 2,36 %.
The minimum anti-HPV titer that confers protective efficacy has not been determined.
Najnižji titer anti-HPV, ki prinaša zaščitno učinkovitost, ni ugotovljen.
The minimum distribution rate is :
Najmanjša gostota vab je:
The minimum effective dose should be used.
Uporabiti je treba najmanjši še učinkoviti odmerek.
The minimum inhibitory concentrations of itraconazole for different Aspergillus isolates in birds in Europe varies between 0.25 and >16 g/ml.
Minimalne inhibitorne koncentracije intrakonazola za različne izolate Aspergillus pri pticah v Evropi so različne, z razponom od 0,25 do > 16 µg/ml.
The minimum recommended dose is 42.3 mg dinotefuran/kg bodyweight and 4.23 mg pyriproxyfen/kg bodyweight.
Minimalni priporočeni odmerek je 42,3 mg dinotefurana/kg telesne teže in 4,23 mg piriproksifena/kg telesne teže.
The minimum recommended dose is 6.4 mg dinotefuran/kg body weight, 0.6 mg pyriproxyfen/kg body weight and 46.6 mg permethrin/kg body weight, equivalent to 0.12 ml of the veterinary medicinal product per kg body weight.
Minimalni priporočeni odmerek je 6,4 mg dinotefurana/kg telesne teže, 0,6 mg piriproksifena/kg telesne teže in 46,6 mg permetrina/kg telesne teže, kar ustreza 0,12 ml zdravila za uporabo v veterinarski medicini/kg telesne teže.
The minimum recommended dose is 6.4 mg dinotefuran/kg body weight, 0.6 mg pyriproxyfen/kg body weight and 46.6 mg permethrin/kg body weight, equivalent to 0.12 ml of the veterinary medicine per kg body weight.
Minimalni priporočeni odmerek je 6,4 mg dinotefurana/kg telesne teže, 0,6 mg piriproksifena/kg telesne teže in 46,6 mg permetrina/kg telesne teže, kar ustreza 0,12 ml zdravila za uporabo v veterinarski medicini/kg telesne teže.
The minor metabolites dexmedetomidine carboxylic acid, 3-hydroxymethyl dexmedetomidine and its O- glucuronide individually comprised 1.11 to 7.66% of the dose.
Manj pomembni presnovki, t.j. deksmedetomidin karboksilna kislina, 3-hidroksimetil deksmedetomidin in njegov O-glukuronid, so ločeno predstavljali od 1,11 do 7,66 % odmerka.
The mist-release button must be pressed firmly all the way in, to release the mist through the nozzle - see picture c.
Gumb za sprostitev meglice morate pritisniti močno povsem do konca noter, da se skozi nastavek sprosti meglica – glejte sliko c.
The mist-release button must be pressed firmly all the way in, to release the mist through the nozzle - see picture c.
Gumb za sprostitev meglice morate pritisniti močno povsem do konca noter, da se skozi šobo sprosti meglica – glejte sliko c.
The mitochondrial membrane is more readily permeable for carglumic acid than for N- acetylglutamate
Mitohondrijska membrana je bolj propustna za kargluminsko kislino kot za N-acetilglutamat.
The mITT population was defined as all randomized subjects who had both a penile curvature deformity measurement and a PDQ assessment at baseline and at one or more subsequent time points. b p-value < 0.01
Populacija mITT je bila opredeljena kot vse randomizirane osebe, ki so imele izmerjeno deformacijo ukrivljenosti penisa in oceno PDQ ob izhodišču in na eni ali več naknadnih časovnih točkah. b vrednost p < 0,01
The mITT population was defined as all randomized subjects who had both a penile curvature deformity measurement and a PDQ assessment at baseline and at one or more subsequent time points. b p-value < 0.05.
Populacija mITT je bila opredeljena kot vse randomizirane osebe, ki so imele izmerjeno deformacijo ukrivljenosti penisa in oceno PDQ ob izhodišču in na eni ali več naslednjih časovnih točkah. b vrednost p < 0,05
The mixed solution can be stored for up to 6 hours in a refrigerator.
Pripravljena mešanica se lahko shranjuje v hladilniku največ 6 ur.
The mixed solution in the vial cannot be stored and should be promptly diluted in an infusion bag; only the diluted solution can be held for up to 24 hours if it is kept cool (2°C – 8°C) and in the dark.
Zmešane raztopine v viali ni možno hraniti in jo je treba takoj razredčiti v infuzijski vrečki; samo razredčeno raztopino je možno hraniti do 24 ur v hladnem (2 °C – 8 °C) in temnem prostoru.
The mixed vaccine can either be stored in a refrigerator (2°C - 8°C) or at room temperature not exceeding 25°C. If the mixed vaccine is stored in a refrigerator, it should be allowed to reach room temperature (for a minimum of 15 minutes) before each withdrawal.
Pripravljeno cepivo lahko shranjujete v hladilniku (2°C - 8°C) ali na sobni temperaturi, ki ne presega 25 °C. Če pripravljeno cepivo shranjujete v hladilniku, ga je treba pred odvzemom posameznega odmerka vsaj 15 minut pustiti da doseže sobno temperaturo.
The mixed vaccine can either be stored in a refrigerator (2°C - 8°C) or at room temperature not exceeding 25°C. If the mixed vaccine is stored in a refrigerator, it should be allowed to reach room temperature (for a minimum of 15 minutes) before each withdrawal.
Pripravljeno cepivo lahko shranjujete v hladilniku (2°C - 8°C) ali na sobni temperaturi, ki ne presega 25 °C. Če pripravljeno cepivo shranjujete v hladilniku, ga je treba pred odvzemom posameznega odmerka vsaj 15 minut pustiti, da doseže sobno temperaturo.
The mixed vaccine can either be stored in a refrigerator (2°C - 8°C) or at room temperature not exceeding 25°C. If the mixed vaccine is stored in a refrigerator, it should be allowed to reach room temperature before each withdrawal.
Pripravljeno cepivo lahko shranjujete v hladilniku (2°C - 8°C) ali na sobni temperaturi, ki ne presega 25 °C. Če pripravljeno cepivo shranjujete v hladilniku, morate poskrbeti, da doseže sobno temperaturo preden izvlečete posamezni odmerek.
The mixed vaccine can either be stored in a refrigerator (2°C - 8°C) or at room temperature not exceeding 25°C. If the mixed vaccine is stored in a refrigerator, it should be brought to room temperature (allow a minimum of 15 minutes) before each withdrawal.
Pripravljeno cepivo lahko shranjujete v hladilniku (2°C - 8°C) ali na sobni temperaturi, ki ne presega 25 °C. Če pripravljeno cepivo shranjujete v hladilniku, ga je treba vsaj 15 minut pustiti na sobni temperaturi, preden izvlečete posamezni odmerek.
The mixed vaccine can either be stored in a refrigerator (2°C – 8°C) or at room temperature (25°C – 30°C).
Pripravljeno cepivo lahko shranjujete v hladilniku (2°C - 8°C) ali na sobni temperaturi (25 °C - 30 °C).
The mixed vaccine can either be stored in a refrigerator (2°C – 8°C) or at room temperature (25°C – 30°C).
Pripravljeno cepivo lahko shranjujete v hladilniku (2°C - 8°C) ali na sobni temperaturi (od 25 °C do 30 °C).
The mixed vaccine can either be stored in a refrigerator (2°C – 8°C) or at room temperature not exceeding 25°C. If the mixed vaccine is stored in a refrigerator, it should be allowed to reach room temperature before each withdrawal.
Pripravljeno cepivo lahko shranjujete v hladilniku (2°C - 8°C) ali na sobni temperaturi, ki ne presega 25 °C. Če pripravljeno cepivo shranjujete v hladilniku, morate poskrbeti, da doseže sobno temperaturo preden izvlečete posamezni odmerek.
The mixed vaccine is a whitish emulsion.
Cepivo, pripravljeno za uporabo, je belkasta emulzija.
The mixed vaccine is a whitish to to yellowish homogeneous milky liquid emulsion.
Cepivo, pripravljeno za uporabo, je belkasta do rumenkasta homogena mlečna tekoča emulzija.
The mixed vaccine is a whitish to yellowish homogeneous milky liquid emulsion.
Cepivo, pripravljeno za uporabo, je belkasta do rumenkasta homogena mlečna tekoča emulzija.
The mixed vaccine is a whitish to yellowish homogeneous milky liquid emulsion.
Pripravljeno cepivo je belkasta do rumenkasta homogena mlečna emulzija.
The mixed vaccines should be administered by subcutaneous injection.
Mešano cepivo je treba dajati subkutano.
The mixed vaccines should be administered by subcutaneous injection.
Mešano cepivo je treba dati subkutano.
The mixing may be done with one teaspoonful (approximately 5 mL) of milk for children weighing up to 5 kg, or with a tablespoonful (approximately 15 mL) of milk or fruit juice for children weighing more than 5 kg, delivered in a baby’s bottle.
Za otroke, ki tehtajo do 5 kg, lahko naredite mešanico z eno čajno žličko mleka (približno 5 ml), za otroke, ki tehtajo več kot 5 kg, pa mešanico z jedilno žlico mleka ali sadnega soka (približno 15 ml) in jo daste iz dojenčkove stekleničke.
The mixture is fed to the infant or young child.
Mešanico dajajte dojenčku ali mlajšemu otroku, da jo zaužije.
The mixture should be administered immediately after preparation.
Mešanico je treba uporabiti takoj po pripravi.
The mixture should then be well shaken until the powder is completely dissolved prior to administration.
Mešanico dobro pretresemo, da se prašek, pred dajanjem, popolnoma raztopi.
The MMR rate at 12, 24, 36, 48, 60 and 72 months is presented in Table 5.
V preglednici 5 so prikazani deleži glavnih molekularnih odzivov po 12, 24, 36, 48, 60 in 72 mesecih.
The mobilisation and apheresis procedures should be performed in collaboration with an oncology-haematology centre with acceptable experience in this field and where the monitoring of haematopoietic progenitor cells can be correctly performed.
Mobilizacijo in aferezne postopke je treba opravljati v sodelovanju z onkološko- hematološkim centrom, ki ima sprejemljive izkušnje na tem področju in v katerem je mogoče pravilno spremljanje krvotvornih matičnih celic.
The mobilisation and apheresis procedures should be performed in collaboration with an oncology-haematology centre with acceptable experience in this field and where the monitoring of haematopoietic progenitor cells can be correctly performed.
Postopek izplavljanja in afereze bi moral potekati v sodelovanju z onkološko- hematološkim centrom, ki ima ustrezne izkušnje na tem področju in v katerem lahko na ustrezen način spremljajo krvotvorne matične celice.
The mobilisation and apheresis procedures should be performed in collaboration with an oncology-haematology centre with acceptable experience in this field and where the monitoring of haematopoietic progenitor cells can be correctly performed.
Postopki izplavljanja (mobilizacije) in afereze se morajo izvajati v sodelovanju z onkološkim-hematološkim središčem, ki ima sprejemljive izkušnje na tem področju, in kjer je mogoče neoporečno izvajati spremljanje hematopoetskih matičnih celic.
The mobilisation and apheresis procedures should be performed in collaboration with an oncology-haematology centre with acceptable experience in this field and where the monitoring of haematopoietic progenitor cells can be correctly performed.
Postopki mobilizacije in afereze morajo biti izvedeni v sodelovanju z onkološkim- hematološkim centrom, ki ima ustrezne izkušnje na tem področju in kjer lahko natančno nadzirajo krvotvorne predniške celice.
The mode of action of itraconazole is based on its highly selective binding ability for fungal cytochrome P- 450 iso-enzymes.
Način delovanja itrakonazola temelji na zelo selektivni sposobnosti vezave na glivične izoencime citokroma P-450.
The mode of action of thiazides is through inhibition of the Na+Cl- symporter perhaps by competing for the Cl- site, thereby affecting electrolyte reabsorption mechanisms: directly increasing sodium and chloride excretion to an approximately equal extent, and indirectly, by this diuretic action, reducing plasma volume, with consequent increases in plasma renin activity, aldosterone secretion and urinary potassium loss, and a decrease in serum potassium.
Tiazidi delujejo tako, da verjetno tekmujejo za vezavno mesto za Cl- ione na skupnem prenašalcu Na+ in Cl- ionov in ga na ta način zavirajo, s tem pa vplivajo na mehanizme reabsorpcije elektrolitov: neposredno povečajo izločanje natrija in klorida v približno enaki meri, posredno pa s takim diuretičnim delovanjem zmanjšajo volumen plazme, s tem povzročijo zvišanje delovanja renina v plazmi, izločanje aldosterona in izgubljanje kalija z urinom ter znižano koncentracijo kalija v serumu.
The mode of action suggests that the effects of L-dopa, dopaminergic agonists, and anticholinergics may be enhanced by concomitant treatment with NMDA-antagonists such as memantine.
Na podlagi mehanizma delovanja je moč pričakovati, da se ob sočasnem zdravljenju z antagonisti NMDA kot je memantin, učinki L-dope, dopaminergičnih agonistov in antiholinergikov, lahko okrepijo.
The mode of action suggests that the effects of L-dopa, dopaminergic agonists, and anticholinergics may be enhanced by concomitant treatment with NMDA-antagonists such as memantine.
Na podlagi mehanizma delovanja se pričakuje, da se učinki L-dope, dopaminergičnih agonistov in antiholinergikov lahko okrepijo ob sočasnem zdravljenju z antagonisti NMDA kot je memantin.
The mode of administration of Livensa makes overdose unlikely.
Zaradi načina odmerjanja zdravila Livensa preveliko odmerjanje ni verjetno.
The model- predicted duloxetine steady state plasma concentrations in paediatric patients were mostly within the concentration range observed in adult patients.
Z modelom predvidene plazmske koncentracije duloksetina v stanju ravnotežja so bile večinoma znotraj obsega koncentracij, izmerjenih pri odraslih.
The modeled treatment effect for the percent change in urine KS, compared to placebo, was -40.7 % (CI95, -49.0, -32.4; p<0.0001) for the 2 mg/kg per week regimen.
Modelirani učinek zdravljenja v deležu spremembe ravni KS v urinu je v primerjavi s placebom znašal -40,7 % (IZ95, -49,0, -32,4; p < 0,0001) pri odmerku 2 mg/kg telesne mase enkrat na teden.
The modeled treatment effect in stairs climbed per minute, compared to placebo, was 1.1 stairs/minute (CI95, -2.1, 4.4; p=0.4935) for the 2 mg/kg per week regimen.
Modelirani učinek zdravljenja v smislu števila stopnic, prehojenih v eni minuti, v primerjavi s placebom, je bil 1,1 stopnice/minuto (IZ95, -2,1, 4,4; p = 0,4935) pri odmerku 2 mg/kg telesne mase enkrat na teden.
The modeled treatment effect in the distance walked in 6 minutes, compared to placebo, was 22.5 m (CI95, 4.0, 40.9; p=0.0174) for the 2 mg/kg per week regimen.
Modelirani učinek zdravljenja v smislu razdalje, prehojene v šestminutnem testu hoje, v primerjavi s placebom, je bil 22,5 m (IZ95, 4,0, 40,9; p = 0,0174) pri odmerku 2 mg/kg telesne mase enkrat na teden.
The moderate number (approximately 450) of prospectively collected pregnancies exposed to infliximab with known outcomes, including a limited number (approximately 230) exposed during the first trimester, does not indicate unexpected effects on pregnancy outcome.
Zmerno število (približno 450) prospektivno zbranih podatkov o izpostavljenosti infliksimabu pri nosečnicah z znanim izidom nosečnosti, med katerimi je bilo manjše število nosečnic (približno 230) infliksimabu izpostavljenih v prvem trimesečju, ne kaže, da bi imelo zdravilo nepričakovane učinke na izid nosečnosti.
The modified intent-to-treat (MITT) group included 465 allogeneic HSCT recipients with 45% of patients having AML.
Spremenjena skupina bolnikov, ki so jih nameravali zdraviti (modified intent-to-treat – MITT), je vključevala 465 prejemnikov homolognih HSCT, od katerih jih je 45 % imelo akutno mieloično levkemijo (AML).
The modified intention to treat (ITT) population included women regardless of baseline HPV status at Day 1, who received at least one vaccination and in whom case counting started at 1 month Postdose
Modificirana ITT (intention-to-treat) populacija je vključevala ženske ne glede na HPV status 1. dan, ki so prejele vsaj en odmerek cepiva, štetje primerov pa se je začelo 1 mesec po cepljenju s
The modified toxin in the vaccine is produced by a method known as ‘recombinant DNA technology’: it is made by bacteria which have received a gene (DNA) that makes them produce the modified toxin.
Modificirani toksin v cepivu pridobivajo z metodo, znano kot „tehnologija rekombinantne DNK, pri kateri bakterije prejmejo gen (DNK), s katerim lahko tvorijo modificirani toksin.
The modified-release tablets are round (diameter 8 mm) and convex.
Tablete s prirejenim sproščanjem so okrogle (s premerom 8 mm) in izbočene.
The modulated infrared beams then enter the infrared detectors, which are double layer transmission detectors with a front, and a rear chamber each filled with one of the isotopicly pure gases (13CO2 or 12CO2, respectively) to be measured.
To so 2-plastni detektorji s prednjo in zadnjo komoro, ki sta napolnjeni z enim od izotopno čistih plinov (13CO2 ali 12CO2), na katerem opravljamo meritve.
The monitoring and treatment schedule should be determined by the treating physician based on the individual patient’s response.
Načrt spremljanja in zdravljenja bolnika mora določiti lečeči zdravnik in sicer glede na odziv posameznega bolnika na zdravljenje.
The monitoring of Methaemoglobin level
Nadzor ravni methemoglobina.
The monitoring of NO2 formation
Nadzor nastajanja NO2.
The monoclonal antibody delivers monomethyl auristatin E to the CD30-positive cancer cells, and once inside the cancer cells, it stops them from dividing, and the cancer cells eventually die.
Monoklonsko protitelo prenese monometil auristatin E do rakavih celic, pozitivnih na CD30, ko pa enkrat dospe v rakave celice, prepreči njihovo delitev, zaradi česar rakave celice sčasoma odmrejo.
The monoclonal antibody is attached to monomethyl auristatin E, a cytotoxic (cell-killing) molecule.
Monoklonsko protitelo se veže na monometil auristatin E, citotoksično molekulo (molekulo, ki uničuje celice).
The monomer is approximately 63 kDa, has 497 amino acids, and the same amino acid sequence as the naturally occurring human enzyme, glucocerebrosidase.
Monomer ima molekulsko maso približno 63 kDa, 497 aminokislin in isto zaporedje aminokislin kot glukocerebrozidaza, naravni encim pri človeku.
The monophosphate metabolite is subsequently converted to the active 5’-triphosphate form, ara-GTP.
Monofosfatni presnovek nato preide v aktivno 5’-trifosfatno obliko, ara- GTP.
The monophosphate metabolite is subsequently converted to the active 5’-triphosphate from, ara-GTP.
Monofosfatni presnovek nato preide v aktivno 5’-trifosfatno obliko, ara- GTP.
The monotherapy and combination regimens have been used for up to 38 and 21 cycles respectively.
Monoterapijo in kombinirani režim se je uporabljal za do 38 oziroma 21 ciklov.
The more sustained release of insulin glargine from the Toujeo precipitate compared to insulin glargine 100 units/ml is attributable to the reduction of the injection volume by two thirds that results in a smaller precipitate surface area.
Podaljšano sproščanje insulina glargina iz precipitata zdravila Toujeo v primerjavi z insulinom glarginom 100 enot/ml je mogoče pripisati zmanjšanju injicirane količine za dve tretjini: posledica tega je manjša površina precipitata.
The morning dose is to be taken at least 30 minutes before the morning meal.
Jutranji odmerek je treba vzeti vsaj 30 minut pred jutranjim obrokom.